Quick Answer
Enliven Therapeutics, Inc. reported Stockholders Equity of $459.60 million for fiscal year 2025.
Enliven Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $459.60M | +48.3% |
| 2024 | $309.85M | +26.0% |
| 2023 | $245.91M | +420.1% |
| 2022 | -$76.83M | -79.1% |
| 2021 | -$42.89M | -150.8% |
| 2020 | $84.44M | +272.9% |
| 2019 | -$48.85M | -85.6% |
| 2018 | -$26.32M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $476.12M | +65.1% | -2.5% |
| June 30, 2025 | $488.47M | +60.2% | +69.4% |
| March 31, 2025 | $288.30M | -9.3% | -7.0% |
| December 31, 2024 | $309.85M | +26.0% | +7.4% |
| September 30, 2024 | $288.40M | +10.2% | -5.4% |
| June 30, 2024 | $304.93M | +9.3% | -4.0% |
| March 31, 2024 | $317.71M | +9.0% | +29.2% |
| December 31, 2023 | $245.91M | +420.1% | -6.1% |
- Enliven Therapeutics, Inc. showed an increase of +48.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Enliven Therapeutics, Inc.’s stockholders equity has grown by 1846.5% (from -$26.32 million to $459.60 million).
- The most recent figure is from Enliven Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: